Hyphenated technique reveals valuable information about plasma proteins
![](/46/pdcnewsitem/04/12/86/postnovapr4-image.png)
Researchers show how an AF4-ICP-MS system is able to obtain valuable information on the multi-element speciation and absolute molecular mass of human plasma proteins such as Albumin and Transferrin.
Postnova Analytics reports on exciting advances in the analysis of plasma proteins using a hyphenated system that couples asymmetric flow Field-Flow Fractionation (AF4) and inductively coupled plasma-mass spectrometry (ICP-MS). In a new application study researchers show how an AF4-ICP-MS system is able to obtain valuable information on the multi-element speciation and absolute molecular mass of human plasma proteins such as Albumin and Transferrin.
Human Serum Albumin (HSA) and Transferrin are the two main plasma proteins that are known to bind and transfer metal ions in biological fluids. Metal-protein complexes are involved in many health studies such as metal-based drugs for cancer or diabetes treatments. Asymmetric flow field-flow fractionation (AF4) is very similar to liquid chromatography, and has been successfully applied to protein fractionation in several biological applications. However unlike liquid chromatography for which fractionation occurs by interaction with a stationery phase, AF4’s lack of stationery phase offers improved recovery for a range of species from complex biological matrices. Further the AF4 technique has been able to achieve this (in some cases) using non-denaturing carriers, which offers significant benefits for the separation of unstable protein metal complexes.
In the application study, a Postnova AF2000 Multiflow Mid Temperature Field-Flow Fractionation system coupled with an Agilent 7700 ICP-MS system was used to separate a mixture of Human Serum Albumin binding 63Cu and Transferrin binding 56Fe metal ions. The AF2000 system separated the proteins by size and the ICP-MS system detected the metal ions to obtain metal distributions of the protein mixture. The researchers demonstrate that AF4-ICP-MS is an excellent tool for the non-denaturing and element-selective detection of plasma proteins.
The demonstrated benefits of the AF4-ICP-MS technique show particular promise for demanding applications in which the two plasma proteins under study act as binders of the same element (e.g., vanadium in Diabetes studies). Other applications under investigation by Postnova, using the AF4-ICP-MS technique, include patient physiology studies involving identification of metal uptake in plasma; investigation and optimization of therapeutic protein and antibody production; detection of protein contamination, and quality control of therapeutic protein and antibodies.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance